MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA - Get Free Report) CEO Erez Aminov sold 55,410 shares of the company's stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $1.39, for a total value of $77,019.90. Following the completion of the sale, the chief executive officer now owns 1,105,790 shares in the company, valued at $1,537,048.10. The trade was a 4.77 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
MIRA Pharmaceuticals Price Performance
MIRA Pharmaceuticals stock opened at $1.27 on Thursday. MIRA Pharmaceuticals, Inc. has a one year low of $0.51 and a one year high of $5.01. The business's fifty day moving average is $1.34 and its 200 day moving average is $1.32. The stock has a market capitalization of $21.03 million, a PE ratio of -2.27 and a beta of 3.09.
MIRA Pharmaceuticals (NASDAQ:MIRA - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.18) by $0.04. As a group, sell-side analysts expect that MIRA Pharmaceuticals, Inc. will post -0.6 EPS for the current fiscal year.
Analysts Set New Price Targets
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
From Crypto Swap Profits | Ad
All of our key indicators are flashing the same signal: an altcoin season is fast approaching.
And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.
Register for the FREE Workshop Now & get $10 in Bitcoin
A number of research firms have recently commented on MIRA. Rodman & Renshaw initiated coverage on MIRA Pharmaceuticals in a research note on Monday, September 30th. They issued a "buy" rating and a $17.00 target price on the stock. Ascendiant Capital Markets started coverage on shares of MIRA Pharmaceuticals in a report on Monday, August 5th. They issued a "buy" rating and a $11.00 target price for the company. Finally, RODMAN&RENSHAW raised shares of MIRA Pharmaceuticals to a "strong-buy" rating in a research report on Monday, September 30th.
View Our Latest Stock Report on MIRA
Institutional Investors Weigh In On MIRA Pharmaceuticals
A hedge fund recently raised its stake in MIRA Pharmaceuticals stock. Suncoast Equity Management raised its stake in shares of MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA - Free Report) by 125.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 90,000 shares of the company's stock after purchasing an additional 50,000 shares during the period. Suncoast Equity Management owned 0.61% of MIRA Pharmaceuticals worth $117,000 as of its most recent SEC filing. 35.16% of the stock is currently owned by hedge funds and other institutional investors.
About MIRA Pharmaceuticals
(
Get Free Report)
MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
